Gemmer Asset Management’s Blueprint Medicines BPMC Stock Holding History

Gemmer Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	–	–	1347
2019 Q3	$0	Buy	+1	New	+$86	﹤0.01%	1388

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Gemmer Asset Management's BPMC Position: Q4 2019 in Review

Gemmer Asset Management sold out of Blueprint Medicines (BPMC) in Q4 2019, closing a stake of 1 share.

Gemmer Asset Management first reported a position in BPMC in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 227 funds tracked by Wall St. Rank hold BPMC as of Q4 2019.

Gemmer Asset Management reported no remaining Blueprint Medicines position as of Q4 2019 after selling out during the quarter.
Gemmer Asset Management sold 1 Blueprint Medicines share in Q4 2019.
Gemmer Asset Management first reported a position in Blueprint Medicines in Q3 2019 and held it in 1 quarter.
Gemmer Asset Management's Blueprint Medicines position peaked at $0 in Q3 2019.
227 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2019.

Based on Gemmer Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.